Rapid Medical Announces Closing of $50m Series D Financing
Rapid Medical, a company focused on the development of responsive, adjustable neurovascular devices, announced today that it has completed an oversubscribed Series D financing of $50M. The proceeds will be used to support the fast commercial growth of the company’s minimally invasive stroke products worldwide. The round was led by MicroPort with participation from CITIC private equity fund (CPE), Deep Insight and existing investors.
Rapid Medical recently announced the FDA clearance of its TIGERTRIEVER™ revascularization device for use in the treatment of ischemic stroke. TIGERTRIEVER is a new class of clot retriever. The device’s intelligent control enables neuro interventionalists to better remove blood clots and restore blood flow to the brain following an ischemic event—a condition that devastates 700,000 Americans annually. TIGERTRIEVER 13, the smallest device in the TIGERTRIEVER portfolio, is the only clot retriever in the world indicated for the removal clots from more distant areas in the brain. TIGERTRIEVER 13 is CE marked and not cleared by the FDA.
The proceeds will be used to expand commercial operations in US and Europe, create additional clinical evidence supporting the superiority of the company’s products, and advance the product development pipeline utilizing company’s proprietary braiding technology platform. In addition, the funding will be used to obtain regulatory approvals in new strategic territories such as China.
“We’ve revolutionized intravascular devices by providing physicians with the ability to remotely adjust devices to the anatomy. We are thrilled that this new round will allow us to expand this mission,” said Ronen Eckhouse, co-founder and CEO of Rapid Medical. “We are excited about the quality of new and existing investors joining this financing.”
As part of the financing round, Chen Chen, a principle at CPE, will join Rapid Medical’s board of directors.
Jefferies LLC served as exclusive placement agent for Rapid Medical in the financing.
About Rapid Medical
Rapid Medical develops the premier responsive interventional devices for endovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER ™ 17 and 21, COMANECI ™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER ™ 13 and XL are also CE marked. More information is available at www.rapid-medical.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MN-PIPER-SANDLER21.6.2021 20:22:10 CEST | Press release
Piper Sandler Advises SK Capital on Sale of Niacet to Kerry
WA-PATTERN-COMPUTER21.6.2021 19:51:07 CEST | Press release
Pattern Computer Discovers New and Novel Methods for Reducing Flight Delays
TBHF21.6.2021 15:47:10 CEST | Press release
Sharjah Honours Kenyan Humanitarian Outfit, RefuSHE, for Pioneering Contributions in Child and Girl-Focused Refugee Development
DEWIZ21.6.2021 15:36:09 CEST | Press release
deWiz Making a Buzz After Closing out Series-A Funding With More Than 5 Million USD Investment
MCG21.6.2021 15:34:08 CEST | Press release
Membership Collective Group Announces Filing of Registration Statement for Proposed Initial Public Offering
NY-AMERICAN-EXPRESS21.6.2021 15:32:08 CEST | Press release
American Express Plans Live Audio Webcast of Second Quarter 2021 Earnings Conference Call
GA-BIOLOG21.6.2021 15:19:06 CEST | Press release
The Blood Center of New Orleans Cooperates With Biolog-id to Enhance Visibility, Availability, and Traceability of Life-saving Blood Components
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom